BlossomHill Therapeutics, Inc. BLSM
13.96 USD -0.88 (-5.93%)
Nov 13, 2026, 10:33 AM EST
13.95 Day range 15.68
11.02 52-week range 27.99
- YTD
- -12.75%
- 1 year
- -12.75%
News
globenewswire.com BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Alignment with the US Food and Drug Administration (FDA) on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 based on favorable PK, safety, and efficacy data to date Announced SOLARA-2,…
benzinga.com BlossomHill Therapeutics Announces Alignment With FDA On 50mg Twice Daily As Recommended Phase 2 Dose For BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027
globenewswire.com BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Alignment with the US Food and Drug Administration on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational…
benzinga.com BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…
benzinga.com BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027 Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND…
benzinga.com Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40 Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.- benzinga.com Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40 Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
benzinga.com Earnings Scheduled For September 18, 2026 Companies Reporting Before The Bell • BlossomHill Therapeutics (NASDAQ:BLSM) is expected to report earnings for its second quarter. Companies Reporting After The Bell This article was generated by…
benzinga.com BlossomHill Therapeutics Q2 EPS $(8.75) BlossomHill Therapeutics (NASDAQ:BLSM) reported quarterly losses of $(8.75) per share. This is a 58.8 percent decrease over losses of $(5.51) per share from the same period last year.
benzinga.com BlossomHill Therapeutics Announces Updated Data From Ongoing Phase 1/2 SOLARA Trial Of BH-30643 In NSCLC Patients With Secondary EGFR Resistance Mutations Such As EGFR C797S 45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat…- benzinga.com LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32 LifeSci Capital initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $32.
- benzinga.com Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36 Leerink Partners initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $36.
- benzinga.com JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28 JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.
- benzinga.com Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30 Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.
benzinga.com This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com HC Wainwright & Co. Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $35 HC Wainwright & Co. analyst Robert Burns initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $35.- benzinga.com Blossomhill Says FDA Grants Fast Track Designation To BH-30643 For Treatment Of Adult Patients With Advanced Or Metastatic EGFR C797S-Positive NSCLC After Prior Treatment With Third-Gen EGFR Tyrosine Kinase Inhibitor BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…